Axiom Biosciences Aims To Be First US Biotech Listed In Hong Kong
Axiom, founded in San Diego in 2018, targets Hong Kong's Main Board by 2027, then a US listing.
- Lead program treats brain injury in newborns, holding two FDA Rare Pediatric Disease Designations.
- Eight grants from US agencies and California funded a firm now partnered with South Korea's Medinno.
- CEO Remo Moomiaie-Qajar cites Hong Kong's "deep biotechnology capital" and Asian clinical partners as the draw.
Why it matters: A California lab lists where the money already lives, not where its passport says it belongs.
Axiom Biosciences GlobeNewswire press release ↗ · Jul 21, 20267/21/26